• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

I型和II型子宫内膜癌的干细胞群有差异吗?一项初步研究。

Is There Any Difference in Stem Cell Population between Type I and Type II Endometrial Cancer? A Pilot Study.

作者信息

Muthuraman N, Thomas Anitha, Samuel Ram Thomas, Mohankumar K M, Abraham Premila

机构信息

Associate Professor, Department of Biochemistry, Christian Medical College, Vellore, Tamil Nadu, India.

Professor, Department of Gynecologic Oncology, Christian Medical College, Vellore, Tamil Nadu, India.

出版信息

J Mother Child. 2025 May 24;29(1):10-19. doi: 10.34763/jmotherandchild.20252901.d-24-00041. eCollection 2025 Feb 1.

DOI:10.34763/jmotherandchild.20252901.d-24-00041
PMID:40433700
Abstract

BACKGROUND

The incidence of endometrial cancer is increasing globally. Cancer stem cells are now considered the driving force for tumour recurrence and metastasis. We studied whether the proportion of cancer stem cell population and stemness gene expression differ in type I and type II endometrial cancer.

MATERIALS AND METHODS

Type I and type II endometrial tumour tissues were obtained from patients who underwent hysterectomy. The tumour tissue was digested using collagenase, and we established a primary culture. In the primary cultures established from these two types of cancer, we used flow cytometry to measure the proportion of the cancer stem cell population expressing CD 133 and CXCR4 on its surface. We also looked for the expression of genes related to stemness, regulators of stemness, and markers of metastasis in both these cancer types.

RESULTS

We found that the proportion of cancer stem cell population that expresses CD133 and CXCR4 was higher in type II endometrial cancer than in type I endometrial cancer. Also, genes (Nanog, ALDH, EZH2) related to stemness and aberrant transcriptome were found to be upregulated in type II endometrial cancer.

CONCLUSION

Our study demonstrates that the proportion of stem cells in type 2 endometrial cancer is higher than in type I endometrial cancer. The findings of this study should lead us to investigate with a larger sample size and see if the increase in the stem cell population in type II endometrial cancer may be the reason for its poor prognosis.

摘要

背景

子宫内膜癌的发病率在全球范围内呈上升趋势。癌症干细胞现在被认为是肿瘤复发和转移的驱动力。我们研究了I型和II型子宫内膜癌中癌症干细胞群体的比例和干性基因表达是否存在差异。

材料与方法

从接受子宫切除术的患者中获取I型和II型子宫内膜肿瘤组织。使用胶原酶消化肿瘤组织,并建立原代培养。在由这两种癌症建立的原代培养物中,我们使用流式细胞术测量表面表达CD133和CXCR4的癌症干细胞群体的比例。我们还在这两种癌症类型中寻找与干性、干性调节因子和转移标志物相关的基因表达。

结果

我们发现,II型子宫内膜癌中表达CD133和CXCR4的癌症干细胞群体比例高于I型子宫内膜癌。此外,发现与干性和异常转录组相关的基因(Nanog、ALDH、EZH2)在II型子宫内膜癌中上调。

结论

我们的研究表明,II型子宫内膜癌中的干细胞比例高于I型子宫内膜癌。这项研究的结果应促使我们用更大的样本量进行研究,看看II型子宫内膜癌中干细胞群体的增加是否可能是其预后不良的原因。

相似文献

1
Is There Any Difference in Stem Cell Population between Type I and Type II Endometrial Cancer? A Pilot Study.I型和II型子宫内膜癌的干细胞群有差异吗?一项初步研究。
J Mother Child. 2025 May 24;29(1):10-19. doi: 10.34763/jmotherandchild.20252901.d-24-00041. eCollection 2025 Feb 1.
2
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织(EORTC)癌症贫血患者促红细胞生成蛋白使用指南:2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
3
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
4
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
6
Interventions for weight reduction in obesity to improve survival in women with endometrial cancer.肥胖症减肥干预措施以提高子宫内膜癌女性的生存率。
Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD012513. doi: 10.1002/14651858.CD012513.pub3.
7
Adjuvant radiotherapy for stage I endometrial cancer.I期子宫内膜癌的辅助放疗
Cochrane Database Syst Rev. 2012 Mar 14(3):CD003916. doi: 10.1002/14651858.CD003916.pub3.
8
Surgery for women with apical vaginal prolapse.阴道顶端脱垂女性的手术治疗。
Cochrane Database Syst Rev. 2016 Oct 1;10(10):CD012376. doi: 10.1002/14651858.CD012376.
9
Short-term and long-term effects of tibolone in postmenopausal women.替勃龙对绝经后女性的短期和长期影响。
Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD008536. doi: 10.1002/14651858.CD008536.pub3.
10
Negative pressure wound therapy for surgical wounds healing by primary closure.负压伤口疗法在一期缝合手术伤口愈合中的应用。
Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD009261. doi: 10.1002/14651858.CD009261.pub7.

引用本文的文献

1
Therapeutic and Prognostic Relevance of Cancer Stem Cell Populations in Endometrial Cancer: A Narrative Review.子宫内膜癌中癌症干细胞群的治疗及预后相关性:一项叙述性综述
Diagnostics (Basel). 2025 Jul 25;15(15):1872. doi: 10.3390/diagnostics15151872.

本文引用的文献

1
Incidence and Trend of Type I and II Endometrial Cancer in Women from Two Population-Based European Cancer Registries (1998-2012).Ⅰ型和Ⅱ型子宫内膜癌在两个基于人群的欧洲癌症登记处的女性中的发病率和趋势(1998-2012 年)。
Int J Environ Res Public Health. 2022 Mar 23;19(7):3789. doi: 10.3390/ijerph19073789.
2
Endometrial cancer.子宫内膜癌。
Nat Rev Dis Primers. 2021 Dec 9;7(1):88. doi: 10.1038/s41572-021-00324-8.
3
The impact of obesity and bariatric surgery on the immune microenvironment of the endometrium.肥胖和减重手术对子宫内膜免疫微环境的影响。
Int J Obes (Lond). 2022 Mar;46(3):605-612. doi: 10.1038/s41366-021-01027-6. Epub 2021 Dec 2.
4
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019.全球、区域和国家层面 1990-2019 年子宫内膜癌发病率和死亡率的变化。
Gynecol Oncol. 2021 May;161(2):573-580. doi: 10.1016/j.ygyno.2021.01.036. Epub 2021 Feb 5.
5
The Great Escape: The Power of Cancer Stem Cells to Evade Programmed Cell Death.《大逃脱:癌症干细胞逃避程序性细胞死亡的能力》
Cancers (Basel). 2021 Jan 17;13(2):328. doi: 10.3390/cancers13020328.
6
Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.癌症干细胞的起源和生物标志物:靶向个体化治疗的新视角。
Front Immunol. 2020 Aug 7;11:1280. doi: 10.3389/fimmu.2020.01280. eCollection 2020.
7
TNNT1, negatively regulated by miR-873, promotes the progression of colorectal cancer.受miR-873负调控的TNNT1促进结直肠癌进展。
J Gene Med. 2020 Feb;22(2):e3152. doi: 10.1002/jgm.3152. Epub 2019 Dec 23.
8
Cancer Stem Cells: From Historical Roots to a New Perspective.癌症干细胞:从历史根源到新视角
J Oncol. 2019 Jun 11;2019:5189232. doi: 10.1155/2019/5189232. eCollection 2019.
9
Cellular Plasticity in Cancer.癌症中的细胞可塑性。
Cancer Discov. 2019 Jul;9(7):837-851. doi: 10.1158/2159-8290.CD-19-0015. Epub 2019 Apr 16.
10
Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success.简明综述:癌症干细胞靶向治疗:迈向临床成功。
Stem Cells Transl Med. 2019 Jan;8(1):75-81. doi: 10.1002/sctm.18-0123. Epub 2018 Oct 17.